Stifel analyst Alex Thompson lowered the firm’s price target on Crinetics (CRNX) to $83 from $84 and keeps a Buy rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRNX:
- Crinetics reports Q4 EPS ($1.29), consensus ($1.37)
- Here is a List of Small-Cap Biotech ETFs to Watch for Big Gains in 2026
- Crinetics price target raised to $84 from $75 at Stifel
- Crinetics doses first patient in BALANCE-CAH trial
- ‘Markets Climb Wall-of-Worry’: Oppenheimer Sees Resilience Driving 2026 and Suggests 2 Stocks to Buy